Education
About Us
Working with TipRanks
Follow Us
Pure Bioscience (PURE)
:PURE
PURE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.05 - $0.21
Previous CloseN/A
Volume1.63K
Average Volume (3M)41.75K
Market Cap
$7.16M
Enterprise ValueN/A
Total Cash (Recent Filing)$202.00K
Total Debt (Recent Filing)$3.98M
Price to Earnings (P/E)―
Beta-0.53
Next Earnings
Jun 12, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding111,856,476
10 Day Avg. Volume36,778
30 Day Avg. Volume41,752
Financial Highlights & Ratios
PEG Ratio-0.51
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-4.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pure Bioscience News
Options Prices
Currently, No data available
---
Ownership Overview
40.91%
Insiders
0.72% Other Institutional Investors
58.37% Public Companies and
Individual Investors
PURE FAQ
What was Pure Bioscience’s price range in the past 12 months?
Pure Bioscience lowest stock price was $0.04 and its highest was $0.21 in the past 12 months.
What is Pure Bioscience’s market cap?
Pure Bioscience’s market cap is $7.16M.
When is Pure Bioscience’s upcoming earnings report date?
Pure Bioscience’s upcoming earnings report date is Jun 12, 2025 which is in 21 days.
How were Pure Bioscience’s earnings last quarter?
Pure Bioscience released its earnings results on Mar 17, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.007.
Is Pure Bioscience overvalued?
According to Wall Street analysts Pure Bioscience’s price is currently Overvalued.
Does Pure Bioscience pay dividends?
Pure Bioscience does not currently pay dividends.
What is Pure Bioscience’s EPS estimate?
Pure Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pure Bioscience have?
Pure Bioscience has 111,856,476 shares outstanding.
What happened to Pure Bioscience’s price movement after its last earnings report?
Pure Bioscience reported an EPS of -$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.286%.
Which hedge fund is a major shareholder of Pure Bioscience?
Currently, no hedge funds are holding shares in PURE
Company Description
Pure Bioscience
Pure Bioscience (PURE) is a biotechnology company specializing in the development and commercialization of antimicrobial products. The company operates primarily within the health and safety sectors, focusing on solutions that combat bacteria, viruses, and fungi. Its core product, Silver Dihydrogen Citrate (SDC), is a patented, non-toxic antimicrobial agent used in various applications, including food safety, healthcare, and consumer products.